Daré Bioscience (NASDAQ:DARE) Stock Passes Below 200 Day Moving Average – Here’s What Happened

Daré Bioscience, Inc. (NASDAQ:DARE)’s stock price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.55 and traded as low as $3.03. Daré Bioscience shares last traded at $3.12, with a volume of 53,089 shares traded.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a research note on Tuesday, December 17th.

Daré Bioscience Stock Up 4.7 %

The firm has a 50-day moving average of $3.46 and a two-hundred day moving average of $3.54. The company has a market capitalization of $29.32 million, a PE ratio of -5.71 and a beta of 1.27.

Hedge Funds Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC increased its holdings in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the period. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.